[go: up one dir, main page]

MX2018000282A - Oxiesteroles y metodos de uso de los mismos. - Google Patents

Oxiesteroles y metodos de uso de los mismos.

Info

Publication number
MX2018000282A
MX2018000282A MX2018000282A MX2018000282A MX2018000282A MX 2018000282 A MX2018000282 A MX 2018000282A MX 2018000282 A MX2018000282 A MX 2018000282A MX 2018000282 A MX2018000282 A MX 2018000282A MX 2018000282 A MX2018000282 A MX 2018000282A
Authority
MX
Mexico
Prior art keywords
oxysterols
methods
formula
compounds
prevention
Prior art date
Application number
MX2018000282A
Other languages
English (en)
Other versions
MX376833B (es
Inventor
G Salituro Francesco
Jean Robichaud Albert
Martinez Botella Gabriel
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2018000282A publication Critical patent/MX2018000282A/es
Publication of MX376833B publication Critical patent/MX376833B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan compuestos de acuerdo con la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de la misma, y composiciones farmacéuticas de la misma; en donde R1, R2, R3, R6, R7, R8, y n son como se definen en la presente. Los compuestos de la presente invención se contemplan útiles para la prevención y tratamiento de una variedad de afecciones.
MX2018000282A 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos. MX376833B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189048P 2015-07-06 2015-07-06
US201662280394P 2016-01-19 2016-01-19
PCT/US2016/041168 WO2017007836A1 (en) 2015-07-06 2016-07-06 Oxysterols and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2018000282A true MX2018000282A (es) 2018-03-08
MX376833B MX376833B (es) 2025-03-07

Family

ID=57686105

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000282A MX376833B (es) 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos.
MX2020011449A MX390302B (es) 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011449A MX390302B (es) 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos

Country Status (30)

Country Link
US (5) US10201550B2 (es)
EP (3) EP3319611B1 (es)
JP (4) JP2018519351A (es)
KR (2) KR20240137111A (es)
CN (2) CN113292623A (es)
AU (3) AU2016289967B2 (es)
BR (2) BR112018000129B1 (es)
CA (1) CA2991214C (es)
CO (1) CO2018000660A2 (es)
CY (1) CY1124496T1 (es)
DK (2) DK3828194T3 (es)
ES (2) ES3035617T3 (es)
FI (1) FI3828194T3 (es)
HR (1) HRP20210526T8 (es)
HU (1) HUE053778T2 (es)
IL (2) IL305404A (es)
LT (1) LT3319611T (es)
MA (2) MA42410B1 (es)
MD (1) MD3319611T2 (es)
MX (2) MX376833B (es)
PE (1) PE20180483A1 (es)
PH (2) PH12021551134A1 (es)
PL (2) PL3828194T3 (es)
PT (2) PT3319611T (es)
RS (1) RS61718B1 (es)
RU (2) RU2744267C2 (es)
SG (1) SG10202010553XA (es)
SI (1) SI3319611T1 (es)
SM (1) SMT202100226T1 (es)
WO (1) WO2017007836A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105246486B (zh) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 神经活性甾类化合物
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
HUE053778T2 (hu) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxiszterinek és ezek alkalmazása
MX2021005052A (es) 2015-07-06 2022-10-11 Sage Therapeutics Inc Oxiesteroles y métodos de uso de los mismos.
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA44526A (fr) * 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
CN119350419A (zh) 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
MA46565A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
EP3568138B1 (en) * 2017-01-13 2025-03-05 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20250319105A1 (en) 2021-06-11 2025-10-16 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
CN113667734B (zh) * 2021-07-16 2022-05-24 四川大学华西医院 Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途
EP4392432A2 (en) * 2021-08-25 2024-07-03 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2023143398A1 (zh) * 2022-01-28 2023-08-03 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2024229297A1 (en) * 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Lymphatic system-targeting compounds
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
TW202508555A (zh) * 2023-07-27 2025-03-01 大陸商珂闌(上海)醫藥科技有限公司 甾類化合物、其製備方法和應用
CN119371475B (zh) * 2023-07-27 2025-11-04 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025221732A1 (en) * 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (es) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
US4358406A (en) 1981-07-27 1982-11-09 Wisconsin Alumni Research Foundation 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
ATE45347T1 (de) 1985-05-30 1989-08-15 Taisho Pharmaceutical Co Ltd Vitamin d3-derivate.
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2183231A1 (en) 1994-02-14 1995-08-17 Ravindra B. Upasani Androstanes and pregnanes for allosteric modulation of gaba receptor
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
DK0808325T3 (da) 1994-11-23 2001-01-29 Cocensys Inc Androstan- og pregnanserier til allosterisk modulering af GABA-receptor
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
KR19990022323A (ko) 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
IL122609A0 (en) 1995-06-23 1998-08-16 Novo Nordisk As Meiosis regulating compounds
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5841272A (en) 1995-12-20 1998-11-24 Sundstrand Corporation Frequency-insensitive current sensor
AU3068497A (en) 1996-05-06 1997-11-26 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
EP1077933A1 (en) 1998-05-11 2001-02-28 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) * 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
YU77701A (sh) 1999-04-29 2005-07-19 Euro-Celtique S.A. 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
US6376530B1 (en) 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1392713B1 (en) 2001-05-03 2007-10-17 The University of Chicago Liver x receptor agonists
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
CA2468989A1 (en) 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
IL164161A0 (en) 2002-03-27 2005-12-18 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
GB0216621D0 (en) 2002-07-17 2002-08-28 Imaging Res Solutions Ltd Imaging compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
WO2004048364A1 (en) 2002-11-22 2004-06-10 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
EP2255812A1 (en) 2004-11-01 2010-12-01 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
JP2009528291A (ja) 2006-02-27 2009-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア オキシステロール化合物及びヘッジホッグ経路
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
SI2097437T1 (sl) 2006-11-21 2015-10-30 Umecrine Cognition Ab Uporaba pregnanskih in androstanskih steroidov za izdelavo farmacevtskega sestavka za zdravljenje obolenj ožs-ja
CN104892498A (zh) 2007-06-20 2015-09-09 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CA2703497A1 (en) 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
WO2009094279A1 (en) 2008-01-25 2009-07-30 Merck & Co., Inc. Quinolizidinone m1 receptor positive allosteric modulators
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088408A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor antagonists for the treatment of neurological conditions
CA2769203A1 (en) 2009-07-29 2011-02-03 University Of Chicago Liver x receptor agonists
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) 2010-05-14 2010-06-30 Ge Healthcare Ltd Method of synthesis
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
WO2012142039A1 (en) 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
AU2012262520A1 (en) 2011-05-27 2014-01-23 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
GEP201706608B (en) 2011-10-07 2017-01-25 Takeda Pharmaceuticals Co 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
US20140149272A1 (en) 2012-08-17 2014-05-29 Trueex Group Llc Interoffice bank offered rate financial product and implementation
US9676812B2 (en) 2012-12-18 2017-06-13 Washington University Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2016505038A (ja) 2013-01-23 2016-02-18 スファエラ ファーマ プライベート リミテッド ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
CN105246486B (zh) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 神经活性甾类化合物
IL286970B2 (en) * 2013-03-13 2024-11-01 Sage Therapeutics Inc Neuroactive steroids and methods of use thereof
HK1222565A1 (zh) 2013-09-25 2017-07-07 范安德尔研究所 高效糖皮質激素
CN112826930A (zh) 2014-02-08 2021-05-25 豪夫迈·罗氏有限公司 治疗阿尔茨海默氏病的方法
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
US10016095B2 (en) * 2014-10-03 2018-07-10 Progressive International Corporation Salad spinner
BR112017007053A2 (pt) 2014-10-07 2018-06-19 Sage Therapeutics Inc compostos neuroativos e métodos de utilização deste composto.
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX2021005052A (es) 2015-07-06 2022-10-11 Sage Therapeutics Inc Oxiesteroles y métodos de uso de los mismos.
HUE053778T2 (hu) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxiszterinek és ezek alkalmazása
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
ES2992037T3 (es) 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
CN119350419A (zh) 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
MA46565A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
CA3067219A1 (en) 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
EP3706755A4 (en) 2017-11-10 2021-11-10 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF GENETIC EPILEPTIC DISEASES
IL308273A (en) 2021-05-04 2024-01-01 Sage Therapeutics Inc Neuroactive steroids for the treatment of mild cognitive impairment associated with Parkinson's disease
US20250319105A1 (en) 2021-06-11 2025-10-16 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
DK3319611T3 (da) 2021-04-12
CA2991214A1 (en) 2017-01-12
BR112018000129B1 (pt) 2024-01-09
MA42410A (fr) 2018-05-16
EP3828194B1 (en) 2025-04-16
US20210145848A1 (en) 2021-05-20
RU2021100620A (ru) 2021-01-29
SG10202010553XA (en) 2020-12-30
IL256710A (en) 2018-03-29
JP2022120062A (ja) 2022-08-17
EP4609866A2 (en) 2025-09-03
ES3035617T3 (en) 2025-09-05
AU2024200268A1 (en) 2024-02-01
US12268697B2 (en) 2025-04-08
HUE053778T2 (hu) 2021-07-28
MD3319611T2 (ro) 2021-06-30
PT3319611T (pt) 2021-04-22
PH12018500065A1 (en) 2018-07-09
AU2016289967B2 (en) 2021-09-09
JP2025026573A (ja) 2025-02-21
FI3828194T3 (fi) 2025-07-17
KR102703602B1 (ko) 2024-09-06
HRP20210526T1 (hr) 2021-05-28
CY1124496T1 (el) 2022-07-22
EP3828194A1 (en) 2021-06-02
BR112018000129A2 (pt) 2018-09-04
IL256710B1 (en) 2023-09-01
KR20180026743A (ko) 2018-03-13
US20190125764A1 (en) 2019-05-02
KR20240137111A (ko) 2024-09-19
MX390302B (es) 2025-03-19
MX2020011449A (es) 2022-02-28
RU2018104278A3 (es) 2019-10-31
JP2021054864A (ja) 2021-04-08
MX376833B (es) 2025-03-07
US20240277733A1 (en) 2024-08-22
JP2018519351A (ja) 2018-07-19
CN108135912A (zh) 2018-06-08
IL256710B2 (en) 2024-01-01
IL305404A (en) 2023-10-01
ES2865258T3 (es) 2021-10-15
PL3319611T3 (pl) 2021-07-12
BR122021005552B1 (pt) 2024-01-02
CO2018000660A2 (es) 2018-07-10
MA42410B1 (fr) 2021-04-30
PH12018500065B1 (en) 2022-11-04
WO2017007836A1 (en) 2017-01-12
LT3319611T (lt) 2021-05-10
PE20180483A1 (es) 2018-03-07
JP7602513B2 (ja) 2024-12-18
AU2021218228B2 (en) 2023-11-16
RU2018104278A (ru) 2019-08-06
BR122023021450A2 (pt) 2023-12-26
AU2016289967A1 (en) 2018-02-01
EP3319611A1 (en) 2018-05-16
SI3319611T1 (sl) 2021-08-31
CN113292623A (zh) 2021-08-24
RU2744267C2 (ru) 2021-03-04
PT3828194T (pt) 2025-07-17
US20180200267A1 (en) 2018-07-19
EP4609866A3 (en) 2025-10-22
EP3319611B1 (en) 2021-01-20
US10201550B2 (en) 2019-02-12
DK3828194T3 (da) 2025-06-30
NZ777726A (en) 2024-05-31
US10765685B2 (en) 2020-09-08
PH12021551134A1 (en) 2024-03-25
SMT202100226T1 (it) 2021-05-07
EP3319611A4 (en) 2019-03-06
NZ738847A (en) 2024-05-31
AU2021218228A1 (en) 2021-09-09
CA2991214C (en) 2024-04-30
HRP20210526T8 (hr) 2021-08-20
CN108135912B (zh) 2021-07-02
US20250387413A1 (en) 2025-12-25
MA55097A (fr) 2022-01-05
RS61718B1 (sr) 2021-05-31
PL3828194T3 (pl) 2025-09-22

Similar Documents

Publication Publication Date Title
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
DOP2017000034A (es) Compuestos de imidazopiridazina
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos
CU20140127A7 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FG Grant or registration